Akrep antivenom üretimi

Akrepler hastalık etkenlerini taşımazlar, ancak çoğu zaman kendilerini korumak amacıyla, insan ve hayvanları sokarak zehirlenmeye neden olurlar. Skorpionizm vakalarının tedavisinde halen kullanılan tek metot akrep antivenom tedavisidir. Antivenom at, koyun, keçi veya deve gibi hayvanlara küçük miktarlarda venom enjeksiyonu ile üretilmektedir. Bu hayvanlarda venomun aktif molekülüne karşı immun bir yanıt gelişir. Hayvanların kanında üretilen antikorlar hayvanlardan düzenli aralıklarla alınır. Toplanan kandan plazma ayrılır. Farklı kimyasal yöntemlerle saflaştırılır ve akrep sokmalarının tedavisinde kullanılır. Türkiye'de, akrep antivenomu 1942 yılından beri Refik Saydam Hıfzısıhha Merkez Başkanlığı'nda üretilmektedir. Bu derlemede, akrep antivenom üretim protokolü hakkında bilgi verilmesi amaçlanmıştır.

Scorpion antivenom production

Scorpions do not harbor agents of disease but, they cause envenomations by stinging humans and animals, most of the time to protect themselves. Scorpion antivenom treatment is still the only method used for therapy of scorpionism cases. Antivenom is produced by injecting a small amount of the venom into an animal such as horse, sheep, goat, or camel. These animals develop an immune response against the venom's active molecule. Antibodies produced in animal's blood were taken in regular intervals. Plasma was separated from collected blood. It purified by different chemical process and used to treat of scorpion stings. In Turkey, scorpion antivenom has been produced in Refik Saydam Hygiene Center since 1942. The protocol of scorpion antivenom production was explained in this study.

___

  • 1. Özkan Ö, Karaer Z. Türkiye akrepleri. Türk. Hij. Den. Biyol.Derg. 2003; 60(2): 55-62.
  • 2. Özkan Ö, Karaer Z. Akreplerin Vücut Yapıları. T.Parazitol Derg. 2004; 28 (1): 54-58.
  • 3. Özkan Ö, Yaman N. Akrepler. Ankara Bölgesi Veteriner Hekimler Odası Bülteni. Ankara, Kasım, 2004; 15-18.
  • 4. Özkan Ö, Yaman N. Akrep Zehri. Ankara Bölgesi Veteriner Hekimler Odası Bülteni. Ankara, Şubat, 2004;19-22.
  • 5. Özkan O, Kat I. Mesobuthus eupeus scorpionism in Sanliurfa region of Turkey. J. Venom. Anim. Toxins inci. Trop. Dis., 2005; 11 (4), 479-491.
  • 6. Özkan O, Kat I. Androctonus crassicauda (Oliver 1807) scorpionism in Sanliurfa region of Turkey. Acta Parasitologica Turcica. 2006; 30(3), 239-245.
  • 7. Özkan O, Adıgüzel S, Ateş C, Bozyigit I, Filazi A. Optimization of Antiscorpion Venom Production. J. Venom. Anim. Toxins incl. Trop. Dis., 2006; 12(2), 297-309.
  • 8. Tulga T. Scorpions found in Turkey and paraspecific action of an antivenin produced with the venom of the species Androctonus crassicauda. J. Turkish Hygiene Exp Bio., 1964; 24; 2,146-155.
  • 9. Tulga T. Cross-reactions between anti-scorpion (Buthus quinquestriatus) and anti-scorpion (Prionurus crassicauda) sera. J. Turkish Hygiene Exp Bio., 1960; 20,191-203.
  • 10. Theakston RD., Warrell DA., Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon. 2003; 41, 541 -557.
  • 11. Sedik SS, Wanas S, Shehata A, Fawaz S. Development of an improved method for production of antiscorpion F(ab)2 fragment of IgG with high yield and potency. Journal of Natural Toxins., 2002; 11(2), 123-132.
  • 12. Krifi MN, El Ayeb M, Dellagi K. The Improvement and Standardization of Antivenom Production in Developing Countries: Comparing Antivenom Quality, Therapeutical Efficiency, and Cost. J. Venom. Anim. Toxins incl. Trop. Dis., 1999; 5(2), 128-141.
  • 13. Isbister GK, Graudins A, White J, Warrell D. Antivenom treatment in arachnidism. Journal of Toxicology Clinical Toxicology. 2003; 41 (3), 291 -300.
  • 14. EMEA. The European Agency for the Evaluation of Medical Products, Evaluation of Medicines for Human Use. Note for Guidance on production and quality control of animal immunoglobulins and immunosera for human use. CPMP/BWP/3354/99. London, 2002,14.
  • 15. Animal Sera. http://www.who.int/bloodproducts/animaLsera/en /Animal sera. Erişim Tarihi 2006.
  • 16. Meddeb-Mouelhi F, Bouhaouala-Zahar B, Benlasfar Z, Hammadi M, Mejri T, Moslah M, Karoui H., Khorchani T, El Ayeb M. Immunized camel sera and derived immunoglobulin subclasses neutralizing Androctonus australis hector scorpion toxins. Toxicon. 2003; 42, 785-791.
  • 17. Christensen PA. Production and standardization of antivenin. In: Lee CY, Handbook of experimental pharmacology. Berlin: Springer Verlag, 1979:825.
  • 18. WHO, Requirements for immune sera of animal origin (Requirements for Biological Substances No. 18). WHO Techn. Rep. Ser., 1969,413,45-60.
  • 19. Hayvan Sağlığı ve Zabıtası Yönetmeliği. Bakanlar Kurulu Karar Tarihi - No: 22.02.1989 89/13838. Dayandığı Kanun Tarihi - No: 08.05.1986 3285. Yayımlandığı Resmi Gazete Tarihi - No: 15.03.1989 20109
  • 20. Ruam Savaş Yönetmeliği. 12 Aralık 1977 tarih ve 16144 sayılı Resmi Gazete.
  • 21. Burnouf T, Griffiths E, Padilla A, Seddik SS, Stephano MA, Gutierrez J. Assesment of the viral safetry of antivenoms fractioned from equine plazma. Biologicals. 2004; 32,115-128.
  • 22. Padilla A, Govezensky T, Possani LD, Larralde C. Experimental envenoming of mice with venom from the scorpion Centruroides limpidus limpidus: differences in mortality and symptoms with and without antibody therapy relating to differences in age, sex and strain of mouse. Toxicon. 2003; 41 (8), 959-965.
  • 23. Balozet L. Scorpionism in the old world. In; Venomous Animal and Their Venoms (Bücherl, W. 8t Buckley, E.E., Eds). Academic Press, New York. 1971: 3, 349-371.
  • 24. Zlotkin E, Miranda F, Rochat H. Chemistry and pharmacology of Buthinae scorpion venoms. In Handbook of Experimental Physiology (Bettini S., Ed.), Springer-Verlag, Heidelberg. 1978; 48, 317-369.
  • 25. Özkan O, Filazi A, The determination of acute lethal dose - 50 (LD50) levels of venom in mice, obtained by different methods from scorpions, Androctonus crassicauda (Oliver 1807). Acta Parasitologica Turcica. 2004; 28(1), 50-53.
  • 26. Özkan O, Adiguzel S, Yakistiran S, Filazi A. Study of the relationship between Androctonus crassicauda (Oliver, 1807; Scorpiones, Buthidae) venom toxicity and telson size, weight and storing condition. J. Venom. Anim. Toxins inci. Trop. Dis., 2006; 12(2), 297-309.
  • 27. Krifi MN, Marrakchi N, El Ayeb M, Dellagi K. Effect of some variables on the in vivo determination of scorpion and viper venom toxicities. Biologicals. 1998; 26,277-288.
  • 28. World Health Organization. Progress in the characterization of venoms and standardization of antivenoms. WHO offset publication No 58. Geneva, 1981.
  • 29. Antivenom Production Process. Lister Institute* of Preventive Medicine. Federal Security Agency U.S. Public Health Service National Institute of Health (Text-book), 1948,161.
  • 30. Antivenom Prospectus. Scorpion antivenom production prospectus used Refik Saydam Hygiene Center of Turkish republic Health Ministry (Prospectus, using instruction). 2004.
  • 31. Veronica M.J. Review of Selected Adjuvants used in Antibody Production. ILAR Journal. 1995; 37(3), 119-125.
  • 32. Yamileth A., Ricardo E., Jose M.G. Effects of bleeding in horses immunized with snake venoms for antivenom production. Revista De Biologia Tropical 1997; 45(3), 1209-1215.
  • 33. European Pharmacopoeia. Viper venom, antiserum, European 1997.0145,1712 1713.
  • 34. Whittemore FW., Keegan HI., Borowitz Jl. Studies of scorpion antivenins. 1. Paraspecificity. Bull. World Health Organ., 1961; 25,185-188.
  • 35. WHO, Requirement for snake antivenins (Requirements for Biological Substances No.21) WHO Techn.Rep.Ser., 1971,21-44.
  • 36. Aşı ve Serum Uygulama Rehberi. Sağlık ve Sosyal Yardım Bakanlığı, Sağlık İşleri Genel Müdürlüğü, No: 426.1973; 104.
  • 37. Feige K, Ehrat FB, Kâstner SBR, Wampfler B. The effects of automated plazmapheresis on clinical, haematological, biochemical and coagulation variables in horses. J.Vet.Med., 2003; 50,185-189.
  • 38. Slovis NM., Acvim D, Murray G. How to Approach whole blood transfusions in horses. AAEP proceedings. 2001; 47,266-269.
  • 39. Antivenom Üretim Protokolü. Refik Saydam Merkez Başkanlığı Akrep antivenom üretim protokolü. 1956.
  • 40. Gutierrez JM, Rojas E, Quesada L, Leon G, Nunez J, Laing GD, Sasa M, Renjifo JM, Nasidi A, Warrell DA, Theakston RD, Rojas G. Pan-African polyspecific antivenom produced by caprylic acid purification of horse IgG. An alternative to the antivenom crisis in Africa. Trans. Royal Soc. Trop. Med. Hygiene., 2005; 99,468-475.
  • 41. Herrera M, Leon G, Segura A, Meneses F, Lomonte B, Chippaux JP, Gutierrez JM. Factors associated with adverse reactions induced by caprylic acid-fractionated whole IgG preparations: comparison between horse, sheep and camel IgGs. Toxicon. 20C5; 46,775-781.
  • 42. Rojas G, Manuel JJ, Gutierrez JM. Caprylic acid fractionation of hyperimmune horse plazma. Description of simple procedure for antivenom production. Toxicon. 1994; 32(3), 351-363.
  • 43. Sezginman N, Demirtaş N. Purification and concentration of antitoxic plazmas J. Turk. Hyg. Exp Biol., 1970; 30(61), 63-72.
  • 44. Smith D. Spitting venom the search for a cure for a Thrid World killer. The Chemical Engineer. 2001; 718, 3839.
  • 45. WHO. Good manufacturing practices for biological products. WHOTechn. Rep. Ser., 1992; 822,20-30.
  • 46. European Pharmacopoeia. Immunsera for Human Use. Part 2. European Treaty Series No. 50.1981,4.
  • 47. Sterilite Testi Ulusal Asgari Uygunluk Kriterleri. 16 Ocak 1996 tarih ve 22525 sayılı Resmi Gazete, Tebliğ No: 96/7. Yürütme ve İdare Bölümü, 42-45.
  • 48. Fiziko-Kimyasal Kontroller Ulusal Asgari Uygunluk Kriterleri. 16 Ocak 1996 tarih ve 22525 sayılı Resmi Gazete, Tebliğ No: 96/9. Yürütme ve İdare Bölümü, 48-51.
  • 49. Zararsızlık Testi Ulusal Asgari Uygunluk Kriterleri. 16 Ocak 1996 tarih ve 22525 sayılı Resmi Gazete, Tebliğ No: 96/8. Yürütme ve İdare Bölümü, 47.